AbbVie's Allergan Aesthetics launches AA Signature in the US

Allergan Aesthetics, an AbbVie company, announced on September 22, 2026, the launch of AA Signature in the United States. Following an international rollout, the program provides healthcare professionals with structured, multimodal consultation frameworks that use Allergan Medical Institute resources alongside products from the company's aesthetics portfolio.

The initiative starts with AA Signature: SKIN360, a consultation approach aimed at patients seeking smoother and more hydrated skin. The protocol integrates three products: SKINVIVE by JUVÉDERM, SkinMedica HA5 Hydra Collagen Hydrator with Vegan Collagen, and BOTOX Cosmetic. Allergan Aesthetics noted that the safety and efficacy of these three products for combined use have not been studied.

According to research cited by the company, 96% of surveyed patients are interested in a comprehensive aesthetic assessment. Practices applying a multimodal planning approach experience 68% higher patient retention compared to those addressing only a single concern. In a separate category-wide study, eight out of 10 patients moved forward with treatment after receiving a comprehensive consultation and agreeing on a plan that included two or more in-office products or procedures.

Nicole Mowad-Nassar, senior vice president at AbbVie and president of Global Allergan Aesthetics, stated that AA Signature helps providers deliver personalized, multimodal assessments backed by the company's product line. Allergan Aesthetics plans to release additional consultation protocols through 2027 to address patient concerns regarding lift, structure, skin firmness, and facial definition.